So Wonhee, Kim Liz, Thabit Abrar K, Nicolau David P, Kuti Joseph L
Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT.
Astellas Pharma Global Department, Northbrook, IL.
Am J Health Syst Pharm. 2017 Jan 1;74(1):e55-e63. doi: 10.2146/ajhp150733. Epub 2016 Dec 22.
The physical compatibility of isavuconazonium sulfate with 95 i.v. drugs during simulated Y-site administration was studied.
Isavuconazonium sulfate for injection and all other drugs were reconstituted according to the manufacturer's recommendation and further diluted with 0.9% sodium chloride injection or 5% dextrose injection to a final concentration (1.5 mg/mL for isavuconazonium sulfate and standard concentrations used clinically for other drugs). A Y site was simulated in glass culture tubes by mixing 5 mL of the tested drug and isavuconazonium sulfate solutions in each diluent. Incompatibility was defined as changes in visual characteristics or increases in turbidity by greater than 0.5 nephelometric turbidity units over the 120-minute experiment.
Of the 95 drugs tested, isavuconazonium sulfate was physically compatible with 66 drugs in 0.9% sodium chloride injection and 60 drugs in 5% dextrose injection. Incompatibility was observed with albumin, amphotericin B deoxycholate, amphotericin B lipid complex, amphotericin B liposome, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline fosamil, ceftazidime, ceftriaxone, cefuroxime, colistimethate sodium, cyclosporine, ertapenem, esomeprazole, filgrastim, fosphenytoin, furosemide, heparin, meropenem, methylprednisolone, micafungin, phenytoin, potassium phosphate, propofol, sodium bicarbonate, sodium phosphate, and tedizolid. Azithromycin, bumetanide, penicillin G potassium, and piperacillin-tazobactam were incompatible with isavuconazonium sulfate in 5% dextrose injection only.
Of the 95 drugs tested, isavuconazonium sulfate 1.5 mg/mL was physically compatible with 66 drugs in 0.9% sodium chloride injection and 60 drugs in 5% dextrose injection. Incompatibility was observed with 18 antimicrobials, including most cephalosporins tested, and 14 other i.v. drugs in at least 1 of the 2 tested diluents.
研究硫酸艾沙康唑在模拟Y型接口给药过程中与95种静脉注射药物的物理相容性。
注射用硫酸艾沙康唑和所有其他药物按照制造商的建议进行复溶,并用0.9%氯化钠注射液或5%葡萄糖注射液进一步稀释至最终浓度(硫酸艾沙康唑为1.5mg/mL,其他药物为临床使用的标准浓度)。在玻璃培养管中通过将5mL受试药物和硫酸艾沙康唑溶液在每种稀释剂中混合来模拟Y型接口。不相容性定义为在120分钟实验过程中视觉特征改变或比浊度增加超过0.5比浊度单位。
在测试的95种药物中,硫酸艾沙康唑在0.9%氯化钠注射液中与66种药物物理相容,在5%葡萄糖注射液中与60种药物物理相容。观察到与白蛋白、去氧胆酸两性霉素B、两性霉素B脂质复合物、两性霉素B脂质体、氨苄西林-舒巴坦、头孢唑林、头孢吡肟、头孢洛林酯、头孢他啶、头孢曲松、头孢呋辛、黏菌素甲磺酸钠、环孢素、厄他培南、埃索美拉唑、非格司亭、磷苯妥英、呋塞米、肝素、美罗培南、甲泼尼龙、米卡芬净、苯妥英、磷酸钾、丙泊酚、碳酸氢钠、磷酸钠和替加环素不相容。阿奇霉素、布美他尼、青霉素G钾和哌拉西林-他唑巴坦仅在5%葡萄糖注射液中与硫酸艾沙康唑不相容。
在测试的95种药物中,1.5mg/mL的硫酸艾沙康唑在0.9%氯化钠注射液中与66种药物物理相容,在5%葡萄糖注射液中与60种药物物理相容。在至少一种测试稀释剂中观察到与18种抗菌药物(包括大多数受试头孢菌素)和其他14种静脉注射药物不相容。